[
  {
    "ts": null,
    "headline": "Amgen Says Imdelltra Reduced Death Risk by 40% in Small Cell Lung Cancer Trial",
    "summary": "Amgen (AMGN) said Monday its Imdelltra drug lowered the risk of death by 40% compared to standard ch",
    "url": "https://finnhub.io/api/news?id=cd1121c70a6968c9d27bc3e80597982813a212de2df250b39f7648123658b806",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748896181,
      "headline": "Amgen Says Imdelltra Reduced Death Risk by 40% in Small Cell Lung Cancer Trial",
      "id": 134968361,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) said Monday its Imdelltra drug lowered the risk of death by 40% compared to standard ch",
      "url": "https://finnhub.io/api/news?id=cd1121c70a6968c9d27bc3e80597982813a212de2df250b39f7648123658b806"
    }
  },
  {
    "ts": null,
    "headline": "ASCO25: Amgen’s Nplate proves effective in GI cancer-linked thrombocytopaenia",
    "summary": "Nplate improved platelet response and reduced therapy modification for patients with chemotherapy-induced thrombocytopaenia.",
    "url": "https://finnhub.io/api/news?id=d7861878d7598db23633cbe515b1cc535e60b18a7fdffe0b33ff71501da1088f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748885928,
      "headline": "ASCO25: Amgen’s Nplate proves effective in GI cancer-linked thrombocytopaenia",
      "id": 134968362,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Nplate improved platelet response and reduced therapy modification for patients with chemotherapy-induced thrombocytopaenia.",
      "url": "https://finnhub.io/api/news?id=d7861878d7598db23633cbe515b1cc535e60b18a7fdffe0b33ff71501da1088f"
    }
  },
  {
    "ts": null,
    "headline": "Amgen (NasdaqGS:AMGN) Announces Positive Results From Phase 3 Lung Cancer Trial",
    "summary": "Amgen (NasdaqGS:AMGN) recently announced interim results from its Phase 3 DeLLphi-304 trial for IMDELLTRA, showing significant improvement in survival outcomes for SCLC patients. This announcement coincided with a 6% rise in the company's stock last week. This gain aligns with the broader market trend, as the market also posted gains recently, despite minor fluctuations due to ongoing China-U.S. trade tensions. The promising clinical trial results likely provided additional positive sentiment...",
    "url": "https://finnhub.io/api/news?id=e5579c5db4802c5b88663553c6a53454527284ba8a6f2d764738a2aaa1c69f81",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748884498,
      "headline": "Amgen (NasdaqGS:AMGN) Announces Positive Results From Phase 3 Lung Cancer Trial",
      "id": 134968363,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NasdaqGS:AMGN) recently announced interim results from its Phase 3 DeLLphi-304 trial for IMDELLTRA, showing significant improvement in survival outcomes for SCLC patients. This announcement coincided with a 6% rise in the company's stock last week. This gain aligns with the broader market trend, as the market also posted gains recently, despite minor fluctuations due to ongoing China-U.S. trade tensions. The promising clinical trial results likely provided additional positive sentiment...",
      "url": "https://finnhub.io/api/news?id=e5579c5db4802c5b88663553c6a53454527284ba8a6f2d764738a2aaa1c69f81"
    }
  },
  {
    "ts": null,
    "headline": "IMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS",
    "summary": "Amgen (NASDAQ:AMGN) today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA® (tarlatamab-dlle) reduced the risk of death by 40% and significantly extended median overall survival (OS) by more than five months compared to standard-of-care (SOC) chemotherapy in patients with small cell lung cancer (SCLC) who progressed on or after one line of platinum-based chemotherapy (median OS: 13.6 vs 8.3 months; hazard ratio [HR], 0.60; 95% confidence interval [CI]: 0.",
    "url": "https://finnhub.io/api/news?id=8a16695b518ef42bbd852035eba4515850b7808df4c1927dd53b9a5d97590323",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748865840,
      "headline": "IMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS",
      "id": 134937219,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ:AMGN) today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA® (tarlatamab-dlle) reduced the risk of death by 40% and significantly extended median overall survival (OS) by more than five months compared to standard-of-care (SOC) chemotherapy in patients with small cell lung cancer (SCLC) who progressed on or after one line of platinum-based chemotherapy (median OS: 13.6 vs 8.3 months; hazard ratio [HR], 0.60; 95% confidence interval [CI]: 0.",
      "url": "https://finnhub.io/api/news?id=8a16695b518ef42bbd852035eba4515850b7808df4c1927dd53b9a5d97590323"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Announces New Interim Results from the Global Phase 3 Dellphi-304 Trial Showing Imdelltra® (Tarlatamab-Llle)",
    "summary": "Amgen announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA® reduced the risk of death by 40% and significantly extended median overall survival by more than...",
    "url": "https://finnhub.io/api/news?id=a7a1221c3818480d79d82982516185537d2f1544959bb9466bdaa4cac6f1e35d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748855128,
      "headline": "Amgen Announces New Interim Results from the Global Phase 3 Dellphi-304 Trial Showing Imdelltra® (Tarlatamab-Llle)",
      "id": 134938125,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "Amgen announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA® reduced the risk of death by 40% and significantly extended median overall survival by more than...",
      "url": "https://finnhub.io/api/news?id=a7a1221c3818480d79d82982516185537d2f1544959bb9466bdaa4cac6f1e35d"
    }
  },
  {
    "ts": null,
    "headline": "Amgen's Imdelltra Shows Lower Risk of Death, Other Benefits in Phase 3 Trial",
    "summary": "By Denny Jacob Amgen said interim results from a Phase 3 trial showed Imdelltra reduced the risk of death and other benefits for patients with small cell lung cancer. The biotechnology...",
    "url": "https://finnhub.io/api/news?id=47210f979d4ec4b2ec8878eca0f47c43537958c782d348d85e74397adcb03ea9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748855108,
      "headline": "Amgen's Imdelltra Shows Lower Risk of Death, Other Benefits in Phase 3 Trial",
      "id": 134938129,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "By Denny Jacob Amgen said interim results from a Phase 3 trial showed Imdelltra reduced the risk of death and other benefits for patients with small cell lung cancer. The biotechnology...",
      "url": "https://finnhub.io/api/news?id=47210f979d4ec4b2ec8878eca0f47c43537958c782d348d85e74397adcb03ea9"
    }
  },
  {
    "ts": null,
    "headline": "Imdelltra Significantly Reduced Risk Of Death By 40% In Small Cell Lung Cancer Patients",
    "summary": "Amgen Inc: * IMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% INSMALLCELL LUNG CANCER PATIENTS * AMGEN INC - IMDELLTRA SHOWS SURVIVAL ADVANTAGE...",
    "url": "https://finnhub.io/api/news?id=a183b03f451f60e4578d91690bf655bfb467e337ad140134c527822971349292",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748852647,
      "headline": "Imdelltra Significantly Reduced Risk Of Death By 40% In Small Cell Lung Cancer Patients",
      "id": 134936766,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "Amgen Inc: * IMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% INSMALLCELL LUNG CANCER PATIENTS * AMGEN INC - IMDELLTRA SHOWS SURVIVAL ADVANTAGE...",
      "url": "https://finnhub.io/api/news?id=a183b03f451f60e4578d91690bf655bfb467e337ad140134c527822971349292"
    }
  },
  {
    "ts": null,
    "headline": "Amgen drug cuts small cell lung cancer death risk by 40%",
    "summary": "Amgen's Imdelltra reducedthe risk of death by 40% compared to chemotherapy for small celllung cancer patients whose disease had worsened after an initialround of chemo, according to interim data...",
    "url": "https://finnhub.io/api/news?id=de923351fee008a70541331a416ffdb0dc9526cc3dcf31a0ef3b01b53df39f04",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748851300,
      "headline": "Amgen drug cuts small cell lung cancer death risk by 40%",
      "id": 134936382,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "Amgen's Imdelltra reducedthe risk of death by 40% compared to chemotherapy for small celllung cancer patients whose disease had worsened after an initialround of chemo, according to interim data...",
      "url": "https://finnhub.io/api/news?id=de923351fee008a70541331a416ffdb0dc9526cc3dcf31a0ef3b01b53df39f04"
    }
  }
]